Cat. No.: HY-N2132

Flavokawain B

(Synonyms: Flavokavain B)

2 Cited Publications

Avis client

Based on 2 publication(s) in Google Scholar

Flavokawain B (Flavokavain B) is an orally active chalcone. Flavokawain B results in activation of caspase-9, -3 and -8, cleavage of PARP. Flavokawain B down-regulates Bcl-2 with concomitant increase in Bax level. Flavokawain B inhibits NF-κB, PI3K/Akt and MAPK signaling pathway. Flavokawain B exhibits Apoptotic effects. Flavokawain B inhibits MMP-9 and promotes ROS generation. Flavokawain B inhibits multiple tumors and inflammation.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.99%
CAS No.: 1775-97-9
Formule: C₁₇H₁₆O₄
Masse moléculaire:284.31

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Flavokawain B Chemical Structure

CAS No.: 1775-97-9

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Publications Citing Use of MedChemExpress (MCE) Flavokawain B

Customer Validation & Images

Cell Proliferation/Viability AssayFlow CytometryWBIn Vivo Efficacy StudyIn Vivo Imaging

Cell Proliferation/Viability Assay
Cell Proliferation/Viability Assay
Cell Proliferation/Viability Assay
Cell Proliferation/Viability Assay
Flow Cytometry
WB
WB
In Vivo Efficacy Study
In Vivo Imaging

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform Caspase :

Voir tous les produits spécifiques à Isoform PARP :

Voir tous les produits spécifiques à Isoform Bcl-2 Family :

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform PI3K :

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform p38 MAPK :

Voir tous les produits spécifiques à Isoform MMP :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>20 μM Compound: 7	Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay	[PMID: 19883086]
A549	IC₅₀	19.7 μM Compound: 21	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 31673309]
A549	IC₅₀	8 μg/mL Compound: Flavokawain B	Inhibition of TNF-alpha-induced NF-kappaB expressed in human A549 cells treated 1 hr after TNFalpha challenge measured after 6 hrs by luciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB expressed in human A549 cells treated 1 hr after TNFalpha challenge measured after 6 hrs by luciferase reporter gene assay	[PMID: 19716299]
B16-F10	IC₅₀	7.7 μM Compound: 1a	Antimelanogenic activity in mouse B16F10 cells assessed as inhibition of melanin production after 4 days Antimelanogenic activity in mouse B16F10 cells assessed as inhibition of melanin production after 4 days	[PMID: 25597012]
Caco-2	IC₅₀	9.9 μM Compound: 2	Cytotoxicity against human Caco2 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human Caco2 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
Fibroblast	IC₅₀	>20 μM Compound: 2	Cytotoxicity against human fibroblasts assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human fibroblasts assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
HaCaT	IC₅₀	13.6 μM Compound: 2	Cytotoxicity against human HaCaT cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human HaCaT cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
HCT-116	IC₅₀	>20 μM Compound: 21	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 31673309]
HCT-116	IC₅₀	7.5 μM Compound: 2	Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
HeLa	IC₅₀	>20 μM Compound: 21	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 31673309]
HSC-3	IC₅₀	4.9 μg/mL Compound: 60	Anticancer activity against human HSC3 cells Anticancer activity against human HSC3 cells	[PMID: 25137491]
Huh-7	IC₅₀	15.9 μM Compound: 2	Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
MCF7	IC₅₀	15.5 μM Compound: 2	Cytotoxicity against human MCF7 assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human MCF7 assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
MCF7	IC₅₀	20 μM Compound: 2f	The compound was tested for antiproliferative activity against MCF-7 human breast cancer cells The compound was tested for antiproliferative activity against MCF-7 human breast cancer cells	[PMID: 11720850]
MDA-MB-231	IC₅₀	16.3 μM Compound: 2	Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
MIA PaCa-2	IC₅₀	18.2 μM Compound: 21	Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 31673309]
NCI-H727	IC₅₀	11.3 μM Compound: 2	Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
NIH3T3	IC₅₀	3.3 μM Compound: 2b	Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay	[PMID: 21112783]
PC-3	IC₅₀	9.1 μM Compound: 2	Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
RAW264.7	IC₅₀	26.5 μM Compound: FK B	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32208222]
RAW264.7	IC₅₀	4.2 μM Compound: FK B	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay	[PMID: 32208222]
REH	IC₅₀	>20 μM Compound: 21	Cytotoxicity against human REH cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity against human REH cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 31673309]
RL	IC₅₀	8.2 μM Compound: 2	Cytotoxicity against human RL assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human RL assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
U-937	IC₅₀	>20 μM Compound: 21	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 31673309]

In Vitro

Flavokawain B (1-5 µg/mL, 18-24 h) inhibits human brain endothelial cell (HUVEC) migration and tube formation^[1].
Flavokawain B (1.25-20 µg/mL, 18 h) induces proliferation inhibition and apoptosis in multiple B-cell lymphoma cell lines through downregulating the PI3K/Akt axis^[3].
Flavokawain B (5-40 µM, 1 h) shows anti-inflammatory activities, with inhibiting production of NO and PGE2 in LPS-induced RAW 264.7 cells^[4].
Flavokawain B (17.6-70.4 μM, 24 h) results in apoptosis of KB cells, evidenced by loss of cell viability, profound morphological changes, genomic DNA fragmentation and sub-G1 phase accumulation^[5].
Flavokawain B (2.5-7.5 µg/mL, 24 h) induces apoptosis in synovial sarcoma cell lines^[6].
Flavokawain B (2.5-7.5 µg/mL, 24 h) inhibits growth of human osteosarcoma cells (143B and saos-2) through G2/M cell cycle arrest and apoptosis^[7].
Flavokawain B (1.25-10 μg/mL, 24 h) induces apoptosis in human oral carcinoma HSC-3 cells through the intracellular ROS generation and downregulation of the Akt/p38 MAPK signaling pathway^[8].
Flavokawain B (2.5-5 μg/mL, 24 h) exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line SK-LMS-1 and ECC-1^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

SUDHL-4, OCI-Ly3, Raji, and Jeko-1
Concentration:

1.25, 2.5, 5, 10, 20 µg/mL
Incubation Time:

24 h, 48 h
Result:

Showed dose- and time-dependent inhibition of cell proliferation (SUDHL-4).
Mildly affected cell (SUDHL-4) viability at a concentration of 1.25 μg/mL (24 h).

Apoptosis Analysis^[3]

Cell Line:

SUDHL-4, OCI-Ly3, Raji, and Jeko-1
Concentration:

2.5, 5, and 10 µg/mL
Incubation Time:

12 h, 24 h
Result:

Increased the number of cleaved PARP and caspase-3 fragments.
Reduced the expression of BCL-XL (an anti-apoptotic member of the BCL-2 family).
Induced the breakdown of MMP.

In Vivo

Flavokawain B (1-2.5 µg/mL, 24 h) suppresses angiogenesis in a zebrafish model^[1].
Flavokawain B (50-200 mg/kg, i.p.) shows anti-inflammatory activities in LPS-induced mice^[4].
Flavokawain B (0.35-0.75 mg/kg, i.p., every 2 days, 27 days) significantly inhibits in vivo growth of human KB cell-derived tumor xenografts in nude mice^[5].
Flavokawain B (20-40 mg/kg, p.o., 7 days) inhibits NF-κB inflammatory signaling pathway activation in colitis mice by targeting TLR2^[10].
Flavokawain B (25 mg/kg, p.o., daily for a week) induces GSH-sensitive oxidative stress in mice through modulation of IKK/NF-κB and MAPK signaling pathways^[11].
Flavokawain B (10-20 mg/kg, i.g., 3 consecutive days) alleviates LPS-induced acute lung injury in mice via targeting myeloid differentiation factor 2^[12].
Flavokawain B (25 mg/kg, i.p., twice-a-week for 2 weeks) in combination with Cisplatin (HY-17394)/Gemcitabine (HY-17026) significantly inhibits tumor growth in a xenograft mouse (SNU-478 cells) model^[13].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Nude mice injected human KB cell^[5]
Dosage:

0.35, 0.75 mg/kg
Administration:

Intraperitoneal injection (i.p.), every 2 days, 27 days
Result:

Showed no loss of body weight.
Showed time-dependent growth inhibition of tumor.
Showed tumor cell inactivity or regression.
Showed augmentation of apoptotic DNA fragmentation.

Chemical Information

CAS No. 1775-97-9
Appearance Solid
Masse moléculaire 284.31
Formule C₁₇H₁₆O₄
Color Light yellow to yellow
SMILES

O=C(C1=C(OC)C=C(OC)C=C1O)/C=C/C2=CC=CC=C2
Synonyms

Flavokavain B
Structure Classification
- Flavonoids
- Chalcones
- Phenols
- Monophenols
Initial Source
- Plants
- other families
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All Cell Proliferation/Viability AssayFlow CytometryWBIn Vivo Efficacy StudyIn Vivo Imaging

Sort by:

Journal Impact Factor

Phytomedicine

The kava chalcone flavokawain B exerts inhibitory activity and synergizes with BCL-2 inhibition in malignant B-cell lymphoma. [Abstract]

2023 Nov:120:155074. PMID: 37716033

Flavokawain B purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

SUDHL-4 cells were pretreated with the pan-PI3K inhibitor LY294002 (20 µM), the Akt inhibitor MK2206 (HY-108232; 4 µM), or the GSK3β inhibitor AR-A014418 (HY-10512; 10 µM) for 1 h followed by treating with FKB (Flavokawain B; HY-N2132) at 2.5 µg/ml for 24 h. Cell viability was measured using the MTS assay and results were shown as the percentage relative to the vehicle-treated control. *p < 0.05, #p < 0.01, and †p < 0.001.

Flavokawain B purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

Raji and Jeko-1 cells were pretreated with the pan-PI3K inhibitor LY294002 (20 µM), the Akt inhibitor MK2206 (HY-108232; 4 µM), or the GSK3β inhibitor AR-A014418 (HY-10512; 10 µM) for 1 h followed by treating with FKB (Flavokawain B; HY-N2132) at 2.5 µg/ml for 24 h. Cell viability was measured using the MTS assay and results were shown as the percentage relative to the vehicle-treated control. *p < 0.05, #p < 0.01, and †p < 0.001.

Flavokawain B purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

SUDHL-4, OCI-Ly3 cells were treated with different concentrations of FKB (Flavokawain B; HY-N2132; 1.25–20 µg/ml) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability (OD value at 490 nm) was measured using the MTS assay. *p < 0.05, #p < 0.01, †p < 0.001, and ‡p < 0.0001 versus control at corresponding time points.

Flavokawain B purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

Raji, and Jeko-1 cells were treated with different concentrations of FKB (Flavokawain B; HY-N2132; 1.25–20 µg/ml) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability (OD value at 490 nm) was measured using the MTS assay. *p < 0.05, #p < 0.01, †p < 0.001, and ‡p < 0.0001 versus control at corresponding time points.

Flavokawain B purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

SUDHL-4 cells were treated with or without FKB (Flavokawain B; HY-N2132; 2.5, 5, and 10 µg/ml) for 12 h. Cells were harvested, washed, and stained with FITC-conjugated annexin V and PE-conjugated PI and each sample was read on flow cytometry. Representative images from at least three experiments were shown and the percentage of apoptotic cells (annexin V-positive cells) was presented. #p < 0.01, †p < 0.001, and ‡p < 0.0001 versus the control.

Flavokawain B purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

SUDHL-4, Raji, and Jeko-1 cells were treated with or without FKB (Flavokawain B; HY-N2132) for 12 h. Expression levels of PARP (full length and cleaved), caspase-3 (full length and cleaved), BAX, and BCL-XL were determined by western blotting. The expression level of GAPDH was used as a loading control. Representative blot images were from three independent experiments.

Flavokawain B purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

SUDHL-4, Raji, and Jeko-1 cells were treated with or without FKB (Flavokawain B; HY-N2132; 10 µg/ml) for 24 h. Levels of total and phosphorylated Akt, mTOR, GSK3β, and S6 were determined by western blotting. The expression level of GAPDH was used as a loading control. Representative blot images were obtained from three independent experiments.

Flavokawain B purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

FKB (Flavokawain B; HY-N2132) decelerates lymphoma growth of SUDHL-4 cells in a xenograft animal model in vivo. BALB/c nude mice were subcutaneously inoculated with 5 × 10⁶ SUDHL-4 cells on day 0. Mice were randomly divided into four groups (n = 5 per group) and treatment with vehicle or the corresponding drugs (FKB (HY-N2132; 0.75, 1.5 mg/kg; every four days; IP), or Doxorubicin (HY-15142A; 5 mg/kg; once a week; IP)) was initiated on day 3. The tumor volume was recorded at indicated days. *p < 0.05 and #p < 0.01 versus the control. Tumors were weighed and photographed after removing from each mouse at the end of the experiment (on day 29). *p < 0.05, #p < 0.01, and †p < 0.001 versus the control.

Flavokawain B purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]

FKB (Flavokawain B; HY-N2132) decelerates lymphoma growth of SUDHL-4 cells in a xenograft animal model in vivo. BALB/c nude mice were subcutaneously inoculated with 5 × 10⁶ SUDHL-4 cells on day 0. Mice were randomly divided into four groups (n = 5 per group) and treatment with vehicle or the corresponding drugs (FKB (HY-N2132; 0.75, 1.5 mg/kg; every four days; IP) was initiated on day 3. Representative images of immunohistochemical staining of Ki-67 on tumor tissues were shown and the percentage of Ki-67-positive cells was calculated. ‡p < 0.0001 versus the control.
Agriculture (Basel)

2025 Feb 22.

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (351.73 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5173 mL

17.5864 mL

35.1729 mL

5 mM

0.7035 mL

3.5173 mL

7.0346 mL

10 mM

0.3517 mL

1.7586 mL

3.5173 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Rossette MC, et al. The In Vitro and In Vivo Antiangiogenic Effects of Flavokawain B. Phytother Res. 2017 Oct;31(10):1607-1613. [Content Brief]

[2]. Li X, et al. Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation. Cell Commun Signal. 2019 Mar 18;17(1):25. [Content Brief]

[3]. Zhao M, et al. The kava chalcone flavokawain B exerts inhibitory activity and synergizes with BCL-2 inhibition in malignant B-cell lymphoma. Phytomedicine. 2023 Nov;120:155074. [Content Brief]

[4]. Lin CT, et al. Anti-inflammatory activity of Flavokawain B from Alpinia pricei Hayata. J Agric Food Chem. 2009 Jul 22;57(14):6060-5. [Content Brief]

[5]. Lin E, et al. Flavokawain B inhibits growth of human squamous carcinoma cells: Involvement of apoptosis and cell cycle dysregulation in vitro and in vivo. J Nutr Biochem. 2012 Apr;23(4):368-78. [Content Brief]

[6]. Sakai T, et al. Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines. J Orthop Res. 2012 Jul;30(7):1045-50. [Content Brief]

[7]. Ji T, et al. Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis. Mol Cancer. 2013 Jun 10;12:55. [Content Brief]

[8]. Hseu YC, et al. The chalcone flavokawain B induces G2/M cell-cycle arrest and apoptosis in human oral carcinoma HSC-3 cells through the intracellular ROS generation and downregulation of the Akt/p38 MAPK signaling pathway. J Agric Food Chem. 2012 Mar 7;60(9):2385-97. [Content Brief]

[9]. Eskander RN, et al. Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. J Obstet Gynaecol Res. 2012 Aug;38(8):1086-94. [Content Brief]

[10]. Chen Y, et al. Flavokawain B inhibits NF-κB inflammatory signaling pathway activation in inflammatory bowel disease by targeting TLR2. Toxicol Appl Pharmacol. 2024 May;486:116922. [Content Brief]

[11]. Zhou P, et al. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. FASEB J. 2010 Dec;24(12):4722-32. [Content Brief]

[12]. Luo W, et al. Flavokawain B alleviates LPS-induced acute lung injury via targeting myeloid differentiation factor 2. Acta Pharmacol Sin. 2022 Jul;43(7):1758-1768. [Content Brief]

[13]. Son JH, et al. Flavokawain B Inhibits Growth of Cholangiocarcinoma Cells by Suppressing the Akt Pathway. In Vivo. 2023 May-Jun;37(3):1077-1084. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5173 mL	17.5864 mL	35.1729 mL	87.9322 mL
	5 mM	0.7035 mL	3.5173 mL	7.0346 mL	17.5864 mL
	10 mM	0.3517 mL	1.7586 mL	3.5173 mL	8.7932 mL
	15 mM	0.2345 mL	1.1724 mL	2.3449 mL	5.8621 mL
	20 mM	0.1759 mL	0.8793 mL	1.7586 mL	4.3966 mL
	25 mM	0.1407 mL	0.7035 mL	1.4069 mL	3.5173 mL
	30 mM	0.1172 mL	0.5862 mL	1.1724 mL	2.9311 mL
	40 mM	0.0879 mL	0.4397 mL	0.8793 mL	2.1983 mL
	50 mM	0.0703 mL	0.3517 mL	0.7035 mL	1.7586 mL
	60 mM	0.0586 mL	0.2931 mL	0.5862 mL	1.4655 mL
	80 mM	0.0440 mL	0.2198 mL	0.4397 mL	1.0992 mL
	100 mM	0.0352 mL	0.1759 mL	0.3517 mL	0.8793 mL

Flavokawain B

2 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Flavokawain B

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library